IL-17 receptor A antigen binding proteins
Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.
1. An isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating said receptor, which antibody comprises a light chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:224, SEQ ID NO:225, and SEQ ID NO:226, respectively, and a heavy chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:146, SEQ ID NO:147, and SEQ ID NO:148, respectively.
2. The antibody according to claim 1 , wherein said antibody is selected from:
a. a recombinant antibody;
b. a single chain antibody;
c. a diabody;
d. a triabody;
e. a tetrabody;
f. a Fab fragment;
g. a F(ab′)2 fragment;
h. an IgD antibody;
i. an IgE antibody;
j. an IgM antibody;
k. an IgG1 antibody;
l. an IgG2 antibody;
m. an IgG3 antibody; and
n. an IgG4 antibody.
3. The antibody according to claim 1 , wherein said antibody comprises a light chain variable domain amino acid sequence of SEQ ID NO: 40 and a heavy chain variable domain amino acid sequence of SEQ ID NO: 14.
4. The antibody according to claim 1 , wherein the antibody is formulated as a pharmaceutical composition.
5. A method of treating psoriasis in a patient in need thereof, comprising administering to said patient a composition comprising a human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating said receptor, which antibody comprises a light chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:224, SEQ ID NO:225, and SEQ ID NO:226, respectively, and a heavy chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:146 SEQ ID NO:147 and SEQ ID NO:148 respectively.